Centene Corporation (CNC) › Analysis

Centene (CNC) stock analysis, November 3, 2026: Uptrend intact after earnings beat, upside math thin

Published November 3, 2026 · updated 2026-11-16 · CNC chart, levels and live analysis

Update, November 16, 2026

Centene (CNC) has risen 5‑day to +9.37% while the S&P 500 fell –1.16% and the XLV health‑care ETF edged up +0.96%, keeping the stock well ahead of both the market and its sector. The price now sits at $74.96, a modest pull‑back from the recent 52‑week high of $76.01 recorded on November 4.

The picture holds – the daily trend still runs with the weekly uptrend, the stock remains above the 50‑day SMA of $67.24 and the 40‑week average, and the key support levels at $70.0 (round) and $69.1 (swing zone) are intact. The breakout target of a close above $76.01 on volume above the 20‑day average has not been met, and volume is down 72.1% versus its 20‑day average, but the stop at $69.09 and upside targets of $80 and $90 remain unchanged.

Recent product announcements – new congestive‑heart‑failure coverage options from Ambetter in North Carolina and Buckeye Health Plan – add to the growth narrative (PR Newswire, PR Newswire) and a $3 M affordable‑housing investment by Health Net underscores broader community engagement (PR Newswire). Analyst sentiment remains bullish with a consensus “Buy” and a mean target of $75.39, only 0.6% below the current price.

Update, November 7, 2026

Centene (CNC) fell 6.0% on November 6, closing at $69.74, after a 1.9% gain over the prior five days. The drop follows a sharp post-election rally—the stock surged nearly 13% on November 4 after Democrats took Congress, per Forbes—but gave back some of those gains as the broader market slipped (SPY -2.7% over five days). The stock remains 8.2% below its November 4 peak of $76.01.

Despite the pullback, the picture holds. The stock is still above its 50-day moving average ($66.66) and 40-week average, and the daily trend remains aligned with the weekly uptrend. The key level to watch is the swing zone at $69.10—a close below that would be the first crack, while a weekly close below $66.66 would change the picture. The upside breakout level remains a daily close above $70.00 on above-average volume, with a target at the 52-week high of $76.01 (reward-to-risk 3.3).

History favors the bulls: after one-day drops of more than 5%, the stock was higher a month later 70.9% of the time (median +5.4%). The 5-day attribution shows CNC outperforming its sector by 1.9 percentage points, though it lags XLV over 50 days (-1.8%). Analysts remain bullish (consensus buy, mean target $75.39), and the stock trades 7.5% below that target. The Medicare Part D premium news (Yahoo Finance) is a potential headwind, but the trend and momentum remain intact.

Update, November 4, 2026

Centene (CNC) surged 13.3% on the day and is up 14.0% over the past five days, outpacing the S&P 500’s -0.5% decline and adding to XLV’s 5.7% gain, driven by a fresh 52‑week high and a wave of bullish health‑insurer coverage after Democrats secured Congress.

The picture holds: the daily trend remains aligned with the weekly uptrend, and the stock stays above the key 70.0 round support and the 69.1 swing‑zone level. Volume is modestly above its 20‑day average (105.9%), and the 50‑day SMA at 66.4 continues to act as a support cushion. The breakout target of 80.0 remains unchanged, with the stop still anchored near 69.15 (70.0 minus a quarter of the 3.4 ATR). A weekly close below the 66.4 SMA would be the trigger that could change the picture.

Recent coverage notes the sector‑wide rally for health insurers, with Investor's Business Daily highlighting Centene’s strong move, while Forbes links the upside to the new political landscape.

Centene Corporation (CNC) beat third-quarter earnings and raised its 2026 guidance on October 27, 2026, yet the shares trade at $67.11, 5.8% below the October 22 peak of $71.24. The weekly uptrend is intact, and the balance of evidence leans positive for the next 2 to 6 weeks, with medium conviction. The upside math is thin, though: the nearest target pays only 0.6 for every 1 risked.

Why it matters

The quarter was a clear beat. Adjusted earnings came in at 58 cents a share against a consensus of 10 cents, and sales of $50.647 billion topped the $47.114 billion estimate, according to Benzinga. Full-year adjusted earnings guidance moved to above $5.20 a share. Seeking Alpha attributes this to stronger Medicare Advantage and Marketplace results and lower interest expense, with Medicare Advantage reaching breakeven a year early.

The market's response says the good news was largely in the price. The stock had gained 62.9% year to date and peaked days before the report, and it has drifted lower since. Over the past five days CNC fell 2.4%, almost exactly in line with the S&P 500 (SPY) at -2.1%. The healthcare sector ETF (XLV) rose 2.8% over the same stretch, so the stock trailed its sector by 5.3 points. Most of the five-day move therefore came from the market, and the gap to the sector is the stock's own. No news item explains that gap. It looks like profit-taking after a large run on low volume, 44% below the 20-day average.

The argument about CNC is about durability. BofA named it the top pick in managed care, with a $82 price target and a Buy rating. It points to a Medicaid medical-cost ratio that improved 30 basis points from the prior quarter. Jefferies raised its target to $69 from $59 but kept a Hold rating, noting unexpected third-quarter headwinds. BofA's note also frames the $5.20 against a consensus of $5.25, so the guidance was not a clean surprise. On the other side, Yahoo! Finance carries Mark Cuban urging investors to drop insurer holdings from retirement funds, a reputational and political overhang rather than an earnings fact. A separate Yahoo! Finance piece lists CNC among stocks that could benefit if Democrats win the Senate in the midterms.

On valuation, 18 analysts rate the stock a consensus buy, with a mean target of $74.5 and a range from $56 to $85. The price is 9.9% below that mean. The spread is wide, which shows analysts disagree on how fast margins recover.

What the evidence says

The long-term thesis is intact. Price is above both its 10-week and 40-week averages, and the 50-day average ($66.17) sits well above the 200-day ($55.55). The stock is up 111% from its 52-week low of $31.80. It is in a late-stage advance that has paused: it is consolidating under the high, not breaking down.

For the next 2 to 6 weeks, the balance of evidence leans positive, with medium conviction (2 of 4 points). Two things support it: the daily trend runs with the weekly uptrend, and CNC has led the S&P 500 over 50 days by 3.2%. Conviction is not higher because the other two points are missing.

The strongest case against is relative weakness. Over 50 days the stock lags XLV by 5.0%, so money has preferred the sector to this name, and the five-day gap of 5.3 points points the same way. RSI is 40, which shows fading momentum, and the bounce of 0.9% today came on thin volume. If the sector keeps outrunning CNC, the positive reading would weaken. It does not tip the balance because price still holds above the 50-day average and the weekly trend is up, but it is why this is a medium reading and not a strong one.

Levels that matter

The structure holds above $66.17, the 50-day average, which is less than a dollar below the current price. A break under it would be the first crack. The trend ends below $63.36, a swing-zone level, and the weekly close is what counts. Under that, the next supports are $60.00 and $59.68.

The breakout level is a daily close above $69.1 on volume above its 20-day average. Resistance then stacks up at $70.00 and the 52-week high of $71.24, which is the only target the map offers nearby. Measured against a stop at $65.47 (the 50-day average minus a quarter of the 14-day ATR), the reward-to-risk is 0.6 to 1. The math does not reach the 3 to 1 that makes a breakout worth the risk. Only a target near the round $80.00 level, well above the 52-week high, would get close to that ratio, and nothing in the current structure points to it.

What would change the picture

A weekly close below $63.36 would end the uptrend as the evidence now reads it. The non-price fact that could do it is a cut to the 2026 adjusted earnings guidance of above $5.20, or a Medicaid or Medicare Advantage cost ratio that gives back its recent improvement. Either would remove the earnings recovery that the shares are being valued on.

What to watch

Get a message when the CNC picture changes — the agent team watches the levels and the news for you.Create a free account

More CNC analyses

Research & education, not advice. MarketCrew is AI-powered and can make mistakes.